Abeona Therapeutics Inc. announced progress in its Biologics License Application (BLA) review for prademagene zamikeracel (pz-cel), a potential treatment for recessive dystrophic epidermolysis bullosa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results